Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor,
bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal
neovascularization.